Zosano Pharma Enters Into Capital Equipment Lease Agreement With Trinity Capital Investment

- September 26th, 2018

Zosano Pharma (NASDAQ:ZSAN) a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology, Adhesive Dermally-Applied Microneedle System announced today that it has entered into a new capital equipment leasing line of up to $14.0 million from Trinity Capital Investment a leading venture debt provider. As … Continued

Zosano Pharma (NASDAQ:ZSAN) a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology, Adhesive Dermally-Applied Microneedle System announced today that it has entered into a new capital equipment leasing line of up to $14.0 million from Trinity Capital Investment a leading venture debt provider.

As quoted in the press release:

This will provide financing for the purchase and installation of an automated coating process at Zosano’s contract manufacturer. This process will be capable of producing as many as 1.5 million doses per year, which is the Company’s target at launch.

As part of this transaction, Zosano paid off in full its outstanding balance of $2.0 million under the Loan and Security Agreement it entered into with Hercules Capital, Inc. on June 3, 2014.

“This new financing partnership with Trinity provides support for commercial manufacture of M207 and is part of our planned technology transfer and scale up activities now underway,” said John Walker, chief executive officer and chairman of the board at Zosano.

Click here to read the full press release.

Should you invest in the 2020 pharmaceutical market?

Read our FREE outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply